To the full analysis
Takeda Pharmaceutical stock: growth
TAKTakeda Pharmaceutical reported $28.21B in revenue for fiscal 2025, down 1.7% on the prior year, up 7.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.7%
per year from 2006 to 2025, per share 7.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
6.8%
per year from 2006 to 2025, per share 7.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 7.1% | 9.6% | 6.7% |
| Revenue per share | 6.9% | 9.5% | 7.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −4.1% | no data | 6.8% |
| Free cash flow per share | −4.3% | no data | 7.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $8.17B | $2.1B | $1.13B |
| 2007 | $8.61B | $2.23B | $1.63B |
| 2008 | $9.63B | $1.47B | $1.8B |
| 2009 | $9.18B | $1.86B | $1.84B |
| 2010 | $8.89B | $1.55B | $1.27B |
| 2011 | $9.45B | $777.49M | $1.66B |
| 2012 | $9.75B | $821.83M | $1.38B |
| 2013 | $10.59B | $667.88M | $439.59M |
| 2014 | $11.13B | −$912.82M | $462.12M |
| 2015 | $11.32B | $501.99M | −$371.74M |
| 2016 | $10.85B | $719.74M | $935.12M |
| 2017 | $11.09B | $1.17B | $1.56B |
| 2018 | $13.13B | $683.33M | $1.22B |
| 2019 | $20.61B | $277.03M | $2.83B |
| 2020 | $20.02B | $2.35B | $4.85B |
| 2021 | $22.35B | $1.44B | $5.87B |
| 2022 | $25.22B | $1.99B | $2.15B |
| 2023 | $26.7B | $902.13M | $1.48B |
| 2024 | $28.69B | $675.83M | $4.24B |
| 2025 | $28.21B | −$954.31M | $3.92B |
Revenue by segment
How Takeda Pharmaceutical Company Limited makes its money and how that has shifted. Names are as the company reports them.
- Gastroenterology31%
- PDT Immunology23%
- Rare Diseases17%
- Oncology13%
- Neuroscience9%
- Vaccines1%
- Other5%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Gastroenterology | $8.5B | $8.81B | 31.2% |
| PDT Immunology | $6.47B | $6.62B | 23.5% |
| Rare Diseases | $4.71B | $4.78B | 16.9% |
| Oncology | $3.51B | $3.63B | 12.9% |
| Neuroscience | $3.54B | $2.59B | 9.2% |
| Vaccines | $346.98M | $373.25M | 1.3% |
| Other | $1.61B | $1.4B | 5% |
| Total revenue | $28.69B | $28.21B | 100% |
Revenue by region
Where Takeda Pharmaceutical Company Limited generates its revenue.
- United States48%
- Europe And Canada25%
- Japan10%
- Latin America6%
- China4%
- Asia, Excluding Japan And China2%
- Other5%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | $5.19B | $9.99B | $9.82B | $10.74B | $13.17B | $13.75B | $14.9B | $13.56B | 48% |
| Europe And Canada | $2.54B | $4.04B | $4.17B | $4.63B | $5.28B | $6.05B | $6.61B | $7.18B | 25.4% |
| Japan | $3.58B | $3.71B | $3.51B | $4.13B | $3.21B | $2.83B | $2.62B | $2.71B | 9.6% |
| Latin America | $551.76M | $898.3M | $761.68M | $804.44M | $1B | $1.24B | $1.48B | $1.59B | 5.6% |
| China | no data | no data | no data | no data | no data | no data | $1.2B | $1.22B | 4.3% |
| Asia, Excluding Japan And China | no data | no data | no data | no data | no data | no data | $622.38M | $617.85M | 2.2% |
| Other | $1.27B | $1.96B | $1.77B | $2.05B | $2.56B | $2.83B | $1.26B | $1.34B | 4.7% |
| Total revenue | $13.13B | $20.61B | $20.02B | $22.35B | $25.22B | $26.7B | $28.69B | $28.21B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.